Safety of Combined Use of ARISTA AH and AdSpray on the Liver Resection Surface: A Clinical Study

未提供0 个研究点目标入组 100 人开始时间: 待定

适应症

试验速览

暂无简介。

•Patients who meet all of the following criteria will be included:
•Patients with primary or metastatic liver tumors (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or metastatic liver cancer) who are clinically indicated for liver resection based on liver function and tumor characteristics
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
•3.Age 18 years or older, regardless of sex

•Patients meeting any of the following criteria will be excluded:
•Patients undergoing liver resection requiring vascular or biliary reconstruction
•Patients with intrahepatic cholangiocarcinoma requiring lymph node dissection
•Patients with impaired liver function (Child-Pugh class B or C)
•Patients with tumor invasion to adjacent organs (excluding the gallbladder)
•Patients with tumor invasion into the inferior vena cava
•Patients deemed unsuitable for participation in this study by the principal investigator
•Patients who decline to participate in this study

发起方

未提供